# Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss

> **NCT02997189** · PHASE2 · TERMINATED · sponsor: **Otonomy, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Cisplatin Induced Hearing Loss

## Interventions

- **DRUG:** OTO-104

## Key facts

- **NCT ID:** NCT02997189
- **Lead sponsor:** Otonomy, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11-15
- **Primary completion:** 2017-09-26
- **Final completion:** 2017-09-26
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Negative Efficacy Results from the recently completed Phase 3 study 104-201506
- **Last updated:** 2020-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02997189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02997189, "Study of OTO-104 in Subjects at Risk From Cisplatin-Induced Hearing Loss". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02997189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*